Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom
VIA EDGAR
December 13, 2023
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn:Cindy Polynice
|
|
|
|
Re: |
Virax Biolabs Group Limited |
|
|
Registration Statement on Form F-3 |
|
|
Filed December 5, 2023 |
|
|
File No. 333-275893 |
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 15, 2023, or as soon as thereafter practicable.
|
|
|
Very truly yours, |
|
|
|
/s/ James Foster |
|
James Foster Chief Executive Officer |
|
|
|
DOCPROPERTY "DocID" \* MERGEFORMAT 23722827.1
240437-10005